Dr. Matthias Gossmann- Statement about FLEXcyte technology from BPS 2020
"Mechanobiology of in vitro assays: Tackling prevailing challanges in pre-clinical drug development.” (1.5 MB)
Common systems for the quantification of cellular contraction rely on animal-based models, complex experimental setups or indirect approaches. Integration into standard lab procedures remains a challenge for current in vitro systems. The FLEXcyte 96 system has the potential to scale-up mechanical testing towards medium-throughput analyses. We show here that, using stem cell-derived cardiomyocytes, this system enables predictive recordings of contractile behaviour in the presence of well-known reference compounds.
Download the material presented at the 64th Annual Meeting of the Biophysical Society below
Dr. Matthias Gossmann
co-founder and CEO at InnoVitro, Germany
The 64th Annual Meeting of the Biophysical Society, San Diego, CA (USA)
Feb 15-19. 2020